The first discussions about value-based metrics development for oncology navigation took place in November 2015 at the Academy of Oncology Nurse & Patient Navigators (AONN+) Annual Conference. Key stakeholders within the AONN+ membership identified an opportunity to develop quality outcome measures for navigation.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer IndexSM (BCI) and its impact on patient confidence in their treatment plan.
Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer IndexSM (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM(BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.